Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022. Ms. Paul brings several years of legal leadership experience in the healthcare industry to Zentalis.
“I am delighted to welcome Andrea to our team. Her extensive expertise in managing complex legal and compliance matters will offer invaluable perspective as we drive forward our clinical plans. I am confident that she will excel in her role of leading our legal division to achieve our near- and long-term milestones,” commented Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis Pharmaceuticals.
Prior to Zentalis, Ms. Paul has served as General Counsel and Corporate Secretary at LogicBio Therapeutics, Inc., where she has led the company’s legal team as a key strategic legal partner in finance, business development and contractual decision-making matters. Previously, she held positions of increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of Vice President, Legal. While at Akebia, Ms. Paul was a key strategic legal partner in the company's merger with Keryx Biopharmaceuticals, Inc. as well as in the company's financing and business development transactions. Prior to Akebia, she served as Senior Corporate Counsel at Momenta Pharmaceuticals, Inc. She began her legal career working as an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Sullivan and Cromwell LLP. Ms. Paul currently chairs the Securities Law Committee of the Boston Bar Association. She received her J.D. from Harvard Law School and her B.A. in Art History from Columbia University.
“I am thrilled to join Zentalis as its General Counsel and support the team’s purpose-driven mission to develop small molecule therapeutics for difficult-to-treat cancers,” said Ms. Paul. “I look forward to working closely with the team and implementing processes to help the Company achieve its corporate and clinical goals.”
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.
For more information, please visit . Follow Zentalis on Twitter at and on LinkedIn at .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding driving forward our clinical plans; the impact of management and personnel changes on our business, operations and financial results and the timing of such changes; and achieving our milestones and corporate and clinical goals. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidates; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; the COVID-19 pandemic has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Investor Contact:
Alexandra Roy
Solebury Trout
Media Contact:
Julia Deutsch
Solebury Trout
